<DOC>
	<DOCNO>NCT00823355</DOCNO>
	<brief_summary>Primary objective evaluate safety profile tolerability oral BCX1777 cohort patient recurrent refractory T/NK-cell malignancy evaluate pharmacokinetics ( PK ) oral BCX1777 .</brief_summary>
	<brief_title>Oral Forodesine Hydrochloride ( BCX-1777 ) Patients With Recurrent Refractory T/NK-cell Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically document histopathological diagnosis biopsy , T/NKcell malignancy ( WHO classification ) . Precursor Tcell lymphoblastic leukemia/lymphoma ( TALL/TLBL ) exclude study A patient recurrent , relapse refractory T/NKcell malignancies receive lease one chemotherapeutic regimen Age 20 great Eastern Cooperative Oncology Group ( ECOG ) performance status:0,1 . Able hospitalize least 15 day first dose In case subject tumor cell rate ≤25 % bone marrow , patient satisfies follow criterion . Neutrophil count : ≥1,200/mm3 Platelet count : ≥75,000/mm3 In case CTCL , tumor cell rate handle ≤25 % . Adequate Liver function : AST , ALT ≤ 5.0 x upper limit normal ( ULN ) Adequate Renal function : Creatinine Clearance ( use cockcroftGault formula ) ≥ 50mL/min Life expectancy least 3 month A patient give write informed consent prior start procedure proper study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>